Correlative data suggest that thyroid hormone receptor-b (TRb) mutations could increase the risk of mammary tumor development, but unequivocal evidence is still lacking. To explore the role of TRb mutants in vivo in breast tumor development and progression, we took advantage of a knock-in mouse model harboring a mutation in the Thrb gene encoding TRb (Thrb PV mouse). Although in adult nulliparous females, a single ThrbPV allele did not contribute to mammary gland abnormalities, the presence of two ThrbPV alleles led to mammary hyperplasia in B36% Thrb PV/PV mice. The ThrbPV mutation further markedly augmented the risk of mammary hyperplasia in a mouse model with high susceptibility to mammary tumors (Pten þ /À mouse), as demonstrated by the occurrence of mammary hyperplasia in B60% of Thrb PV/ þ Pten þ /À and B77% of Thrb
Introduction
Thyroid hormone receptors (TRs) belong to the superfamily of nuclear receptors that are liganddependent transcription factors. Two TR genes, THRA and THRB, located on chromosomes 17 and 3, respectively, encode four thyroid hormone (T3)-binding receptors: TRa1, TRb1, TRb2 and TRb3. They bind T3 that has critical roles in differentiation, growth and metabolism (Yen, 2001) .
Several findings support the notion that mutations of TRs can be associated with cancer. Early evidence suggested that mutated TRs could be involved in carcinogenesis came from the discovery that v-erbA, a highly mutated chicken THRA1 that has lost the ability to activate gene transcription, leads to neoplastic transformation in erythroleukemia and sarcomas (Sap et al., 1989; Wallin et al., 1992; Thormeyer and Baniahmad, 1999) . That male transgenic mice overexpressing v-erbA develop hepatocellular carcinomas, provided the evidence that v-erbA oncoprotein can promote neoplasia in mammals through its dominant-negative activity (Barlow et al., 1994) . Knock-in mice harboring a germ-line mutation in Thrb (Thrb PV ), leading to the loss of T3 binding and dominant-negative activity, develop thyroid cancer (Suzuki et al., 2002; Furumoto et al., 2005) . Abnormal expression and somatic mutations of TRs have been observed in an array of human tumors, including those of the thyroid (Wallin et al., 1992; Bronnegard et al., 1994; Puzianowska-Kuznicka et al., 2002) , liver (Lin et al., 1999) and breast (Silva et al., 2002; Li et al., 2002b) .
Although the functions of most members of the nuclear receptor superfamily in breast tumor biology have been documented (Conzen, 2008) , much less is known about TRs. Low circulating thyroid hormone levels (hypothyroidism) have been proposed to favor mammary hyperplasia in rodents and the development of breast tumors (Mittra, 1974) . Loss of TRb expression by gene deletion or promoter hypermethylation or production of abnormal TRb proteins following THRB mutations has been reported in breast tumors. These correlative observations suggest that TRb may well act as a tumor suppressor (Ali et al., 1989; Silva et al., 2002; Li et al., 2002b) . However, a direct demonstration that TRb mutations participate in the development and/or progression of breast tumors is still lacking.
The Thrb PV mouse (Kaneshige et al., 2000) offers us the unique opportunity to explore in vivo the role of a TRb mutant (hereafter named TRbPV) in breast tumor development and progression. The Thrb PV mouse was created by a targeted mutation of the thyroid hormone receptor-b (TRbPV) through homologous recombination and Cre-LoxP system. TRbPV has a C insertion at codon 448 that produces a frameshift in the 14 C-terminal amino acids of TRb1 (Parrilla et al., 1991) . TRbPV has completely lost T3 binding and exhibits potent dominant-negative activity (Meier et al., 1992) . In this study, we took advantage of the Thrb PV mouse model to analyze the effect of a single or double mutation of Thrb in nulliparous female mice. We also determined whether the TRbPV mutation can enhance the development and the progression of mammary tumors in a mouse model prone to mammary hyperplasia and tumors (Pten þ /À mice) (Stambolic et al., 2000) . The tumor suppressor Pten (phosphatase and tensin homolog deleted from chromosome 10) encodes a dual protein/lipid phosphatase, which counteracts the phosphatidylinositol 3-kinase signaling pathway (Eng, 2002) .
Importantly, we show here that the homozygous Thrb PV mutation alone induces mammary gland hyperplasia, with extensive lobulo-alveolar development. In Pten þ /À mice, the heterozygous or homozygous Thrb PV mutation further increased the occurrence of mammary hyperplasia. In addition, we show that the mutation of a single copy of Thrb doubled the percentage of Pten þ /À females to develop mammary tumors. By characterizing mammary gland abnormalities in females with the Thrb PV mutation, we have demonstrated for the first time that mutations of TRb increase the risks in mammary preneoplasia and tumor. We have also uncovered that TRbPV leads to sustained signal transducer and activator of transcription (STAT5) signaling to promote mammary hyperplasia and tumorigenesis.
Results
The TRbPV mutation increases the occurrence of mammary hyperplasia The effect of a dominant-negative TRb mutation on the development of breast cancers was studied by using mice, heterozygous or homozygous for the TRbPV mutation (Thrb PV/ þ and Thrb PV/PV mice). Mammary gland morphology was assessed on whole-mount preparations by analyzing the lobulo-alveolar development and duct diameter in 3-to 9-months-old nulliparous mice ( Figure 1A ; n ¼ 9-14 mice per genotype). All mammary glands analyzed could be assigned the following stages: (1) normal structure similar to the one of young virgin mice, (2) increased number of ramifications and slightly increased alveolar size, (3) strongly increased number of ramifications with strongly increased alveolar size associated or not with moderate ductal dilatation and (4) extreme alveolar size covering the space between the ducts accompanied by ductal dilation, similar as what is observed in a midterm pregnant wild-type mouse ( Figure 1A ). Most wild-type mammary glands were at stage 1 and did not develop beyond stage 2. Whereas mammary gland development in Thrb PV/ þ mice was similar to that of wild types, 36% of Thrb PV/PV mice displayed extensive development, which was classified into stages 3 (18%) and 4 (18%). The increased lobulo-alveolar development was accompanied by an approximately twofold increase in duct diameter as compared with wild-type mice. These results indicate that the homozygous Thrb PV mutation leads to mammary gland hyperplasia.
To determine whether Thrb PV could further function as a modifier to enhance the occurrence of mammary hyperplasia in a mouse model predisposed to mammary hyperplasia and tumors, Thrb PV mutant mice were crossed with Pten þ /À mice to obtain Thrb
and Thrb PV/PV Pten þ /À mice. The loss of one Pten allele in female mice was previously reported to increase the predisposition of mammary glands to hyperplasia and tumors. In line with the previous observations that the loss of one Pten allele in female mice increases the risk of mammary hyperplasia (Stambolic et al., 2000) , 33% of nulliparous Thrb þ / þ Pten þ /À mice had extensive mammary development to stages 3 (11%) and 4 (22%) ( Figure 1A) . Strikingly, the Thrb PV mutation dramatically increased the occurrence of such abnormalities in Pten þ /À females. Indeed, 60% of Pten þ /À females heterozygous for Thrb PV (Thrb PV/ þ Pten þ /À mice) had aberrant lobulo-alveolar development to stages 3 (14%) and 4 (46%) ( Figure 1A ), and increased ductal dilatation ( Figure 1B ). In Pten þ /À females homozygous for Thrb PV (Thrb PV/PV Pten þ /À mice), this percentage was further increased to 77% (31% at stage 3 and 46% at stage 4) ( Figure 1A ), and was accompanied by a dramatically increased ductal dilation (approximately threefold; Figure 1B ).
The TRbPV mutation increases the occurrence of mammary tumors in Pten þ /À mice Mammary hyperplasia can proceed to tumorigenesis. To determine whether the Thrb PV mutation leads to mammary tumors, and/or enhances the occurrence of mammary tumors in Pten þ /À mice, pathological analyses of the mammary glands were performed after the death or humane end point sacrifice of the animals. A low percentage (B5%) of wild-type females and Thrb PV/ þ Pten þ / þ mice, which displayed similar life expectancy (B24.4 months and 25.4 months, respectively; Figure 2A ) developed mammary tumors. As previously reported (Guigon et al., 2009) Figure 2A ) as a result of thyroid cancer. Owing to their early death, only a few of them displayed mammary tumors (6.6% (n ¼ 1 out of 15 mice) and 7.7% (n ¼ 2 out of 26 mice) of Thrb PV/PV Pten
females, both of which had similar life expectancies (B10 months, Figure 2A ), did not present with thyroid cancer, but displayed mammary tumors ( Figure 2B , arrow), as previously reported for the Pten þ /À mouse (Stambolic et al., 2000) . Notwithstanding, there was an increase by more than twofold in the percentage of Thrb PV/ þ Pten þ /À females with mammary tumors (59%) as compared with Thrb þ / þ Pten þ /À females (27.3%) ( Figure 2C ). Pathological analyses showed that both the genotypes displayed macroscopic fibroadenomas (Figure 2Da ), which are benign lesions, and adenocarcinomas ( Figure 2Db ). Tumor latency was the same in both groups and reached B11 months. These results demonstrate for the first time that a dominant-negative mutation of Thrb on a single allele enhances the predisposition of mammary glands to neoplastic transformation.
The TRbPV mutation leads to sustained activation of the STAT5 signaling pathway and increased cell proliferation in the mammary gland The overactivation of the prolactin (PRL)-STAT5 pathway can lead to the development of mammary tumors (Wennbo et al., 1997; Vonderhaar, 1999; Iavnilovitch et al., 2004; Manhes et al., 2006; Eilon et al., 2007) . Physiologically, PRL influences the mammary gland during development and growth, and stimulates milk gene transcription (Ormandy et al., 1997) . Binding of PRL to its receptor induces the phosphorylation and activation of STAT5. Phosphorylated STAT5 dimerizes and translocates into the nucleus to activate genes involved in cell proliferation during pregnancy, and in production of milk, such as Csn2 encoding b-casein.
The fact that the Thrb PV mutation was associated with a higher occurrence of mammary hyperplasia and mammary tumors in Thrb (Figures 1 and 2C ) led us to hypothesize that the PRL-STAT5 signaling pathway could be aberrantly activated in Thrb
Pten þ /À mammary glands to contribute to mammary gland abnormalities. To test this hypothesis, we performed immunohistochemistry studies of phosphorylated STAT5 (P-STAT5) and total STAT5 in the mammary glands of nulliparous Thrb
As shown in Figures 3Aa and b, P-STAT5 was undetectable in the mammary glands of Thrb
Pten þ /À females, although numerous epithelial cells showed a prominent total STAT5 staining in the cytoplasm (arrows, Figures 3Ad and e) . In contrast, most of the epithelial cells were positively stained for both P-STAT5 and total STAT5 in the mammary glands of Thrb PV/ þ Pten þ /À females (Figures 3Ac and f). While P-STAT5 was observed in the nucleus (arrowhead, Figure 3Ac ), total STAT5 was detected in both the nuclear (arrowheads, Figure 3Af ) and cytoplasmic compartments (arrow, Figure 3Af ). The findings from immunohistochemical analysis were further confirmed by western blot analysis. Consistently, a marked increased phosphorylated STAT5 in the breast tumors of Thrb PV/ þ Pten þ /À mice was evident (lanes 5 and 6, upper panel, Figure 3B ) as compared with that in the mammary glands of nulliparous Thrb þ / þ Pten þ / þ mice (lanes 1 and 2, upper panel, Figure 3B ) and Thrb
þ /À mice (lanes 3 and 4, upper panel). In contrast, no apparent changes in total STAT5 were detected in the mammary glands of nulliparous Thrb Figure 3B ).
We then evaluated the extent of cell proliferation in the mammary glands, by performing immunohistochemistry with the cell proliferation marker Ki-67. There were virtually no Ki-67-positive cells in wild-type (Figure 3Ca) , and very few Ki-67-positive cells in Thrb Figure 3Cb ), indicative of no or minimal cell proliferation. In contrast, most of the mammary epithelial cells displayed Ki-67 staining in Thrb PV/ þ Pten þ /À mammary glands, a result that is consistent with the occurrence of mammary hyperplasia (Figure 1 ) and the increased activation of STAT5 ( Figures 3A and B) . In addition, there was an increased expression of the STAT5 target gene Csn2 mRNA levels in Thrb
mammary glands when compared with Figure 3D ).
Liganded TRb but not TRbPV represses STAT5 signaling to prevent cell proliferation We then evaluated whether the increased STAT5 activation observed in the mammary glands of Thrb PV/ þ Pten þ /À mice could result from increased secretion of PRL by the pituitary. However, in females with the TRbPV mutation, there was no significant change in the levels of PRL in the serum (Figure 4a ) or in the pituitary (Figure 4b ), suggesting that the abnormalities detected in Thrb PV/ þ Pten þ /À mice were not due to the changes of serum PRL levels. As it was reported that PRL-STAT5 signaling pathway could be modulated by cross talk with members of the nuclear receptor family, such as glucocorticoid receptors (Zhang et al., 1997; Wyszomierski et al., 1999) , we considered the possibility that TRb could modulate the STAT5 signaling pathway. To test this hypothesis, we performed cell-based studies with a breast cancer cell line (T47D) that is responsive to PRL by expressing Flag-TRb or Flag-TRbPV via adenoviral infection. Cells harboring vector only were used as negative controls. In the absence of PRL, total STAT5 was detected by western blot in the three groups, but P-STAT5 was barely detectable (Figure 5a , lanes 1, Figure 3 The TRbPV mutation aberrantly activates STAT5 signaling to increase cell proliferation. (A) Immunohistochemistry of P-STAT5 on mammary tissue sections in Thrb
Tissue sections were counterstained with hematoxylin (blue). (lanes 3 and 4) and Thrb PV/ þ Pten þ /À (lanes 5 and 6) mice. Total lysates (50 mg) were analyzed as described in Materials and methods. The lanes are marked (n ¼ 2 per genotype). (C) Assessment of cell proliferation by Ki-67 immunohistochemistry on mammary tissue sections in Thrb
Tissue sections were counterstained with hematoxylin (blue). (D) Levels of Csn2 encoding b-casein in the mammary glands of Thrb
Shown are Csn2 mRNA levels determined by real-time reverse transcriptase-PCR and normalized to Gapdh (glyceraldehyde-3-phosphate dehydrogenase) mRNA levels. Figure 4 Prolactin production is not significantly altered in mice with the TRbPV mutation. (a) Prolactin serum levels in nulliparous mice of the six genotypes. The estrous cycle was monitored daily with a vaginal impedance checker (Muromachi Kikai, Tokyo, Japan) and females were bled when not at the proestrus stage to avoid the serum prolactin peak. Serum prolactin levels were measured by radioimmunoassays at the National Hormone & Peptide Program, Harbor-UCLA Medical Center (Dr AF Parlow). (b) Prolactin content in the pituitaries of nulliparous mice of the six genotypes. Pituitary lysates preparation and western blots were carried out following a procedure previously described (Guigon et al., 2008) . The anti-prolactin antibody was purchased from the National Hormone & Peptide Program, Harbor-UCLA Medical Center. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as a loading control.
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). The treatment with T3 did not induce STAT5 phosphorylation (Figure 5a lanes 2, 6 and 10) . In contrast, PRL treatment resulted in a robust increase in STAT5 phosphorylation in Flag-TRb-and FlagTRbPV-expressing cells or in control cells with the empty vector (Figure 5a, lanes 3, 7 and 11) . Strikingly, the ratio of P-STAT5 to total STAT5 was decreased by approximately twofold after T3 treatment in Flag-TRb cells, but neither in Flag-TRbPV cells nor in control cells (Figure 5a , compare lane 3 with 4, lane 7 with 8 and lane 11 with 12).
We further determined the effect of T3 treatment on STAT5 activity by reporter gene luciferase assays with the pGL4-CISH reporter gene containing four STAT5 binding sites (Fang et al., 2008) . T47D cells were transfected with pcDNA3.1-TRb, pcDNA3.1-TRbPV or pcDNA3.1. Minimal reporter activity was detected in the three groups in the absence of PRL (Figure 5b) . In control cells, as in TRb-and TRbPV-expressing cells, PRL treatment strongly increased luciferase activity (Figure 5b) . The co-treatment with T3 induced an B2.5-fold decrease in luciferase activity in Flag-TRb cells (Figure 5b, compare lanes 3 and 4) . In contrast, there was no effect of T3 in TRbPV-expressing cells (Figure 5b compare lanes 7 and 8) or in control cells (Figure 5b, compare lanes 11 and 12) , which displayed sustained luciferase activity. These results indicate that STAT5 activity is normally repressed by TRb in the presence of T3, but that it is not repressed by TRbPV which has lost T3 binding capacity, thus resulting in the persistent activation of STAT5 signaling pathway in TRbPV-expressing cells.
Ccnd1, encoding cyclin D1, is a known STAT5 downstream target gene (Turkson, 2004 ) that has a critical role in early checkpoint regulation at the G1 phase of the cell cycle. We therefore evaluated whether PRL-STAT5-induced activation of cyclin D1 could be affected by TRb in the presence of T3. Indeed, in Flag-TRb-expressing cells, cyclin D1 protein abundance was decreased in the presence of T3 (compare lanes 3 and 4, Figure 5c ). In contrast, in Flag-TRbPVexpressing cells, no apparent decreases were detected in the presence of T3 (compare lanes 7 and 8, Figure 5c ), or in control cells (lanes 11 and 12, Figure 5c ). These findings indicate that in the presence of T3, TRb acts to suppress cell proliferation via decreasing cyclin D1 protein levels. In contrast, persistent activation of STAT5-cyclin D1 was sustained in Flag-TRbPV-expressing cells.
Discussion
Breast cancer is the most common neoplasia and the second cause of cancer deaths in women in western countries (Jemal et al., 2010) . Genetic mutations, either inherited or sporadic, as well as dysregulation of ovarian hormone signaling are known to contribute to the development and progression of breast cancers. A potential role of T3 was first postulated by Beatson's (1896) study, in which the use of thyroid extracts to treat a patient with metastatic breast cancer was described. Since then, many studies have investigated the potential association of hypo-or hyperthyroid disorders with breast cancer in the past decades, but without clear conclusions (Zumoff et al., 1981; Kalache et al., 1982; Brinton et al., 1984; Lemaire and Baugnet-Mahieu, 1986; Takatani et al., 1989; Franceschi et al., 1990; Goldman et al., 1992; Smyth, 1993; Giani et al., 1996; Simon et -4) , Flag-TRbPV (lanes 5-8) adenovirus constructs or with the vector only adenovirus (lanes 9-12) were incubated with or without T3 and PRL for 24 h, as described in Materials and methods.
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CJ Guigon et al et al., 1986; Alberg and Helzlsouer, 1997; Conde et al., 2006) . Moreover, silencing of the THRB gene by promoter hypermethylation, or the expression of truncated TRb has been reported in human breast cancers (Silva et al., 2002; Li et al., 2002b) . However, the relation between thyroid status or TRb mutations and the pathogenesis of human breast cancer is not understood (Hedley et al., 1981; Smyth, 1997; Strain et al., 1997) . The study of a unique model with a mutation in Thrb offers the opportunity to evaluate for the first time the role of TRb mutants in mammary tumorigenesis. Here, we report that the mutation of Thrb on two alleles led to mammary gland hyperplasia in more than one-third of the animals. In addition, we found that ThrbPV dramatically enhanced the occurrence of mammary hyperplasia in Pten þ /À mice that are prone to develop mammary hyperplasia and tumors, as shown by the observation that B60% of nulliparous Thrb PV/ þ Pten Bachelot A, Binart N, 2007) . Consistent with the well-established role of PRL in normal mammary development and function, multiple studies using various experimental approaches implicate PRL in both the pathogenesis and the progression of mammary neoplasia in rodents (Vonderhaar, 1999; Barash, 2006) . Binding of PRL to its receptor induces the phosphorylation and activation of the transcription factor STAT5. Phosphorylated STAT5 translocates to the nucleus, where it regulates the expression of milk genes, such as b-casein, and genes involved in cell proliferation and survival. In line with the observation that excessive PRL stimulation of the mammary gland leads to the development of tumors, overexpression of constitutively active STAT5 in the mammary gland leads to the development of mammary tumors in multiparous mice (Iavnilovitch et al., 2004) . High levels of STAT5 phosphorylation have been observed in human breast tumors (Cotarla et al., 2004) . These observations prompted us to determine whether overactivated PRL-STAT5 pathway could contribute to the increased occurrence of mammary tumors in Thrb PV/ þ Pten þ /À mice as compared with Thrb þ / þ Pten þ /À mice. Our in vivo studies showed a strong activation of STAT5 in the mammary glands of Thrb PV/ þ Pten þ /À mice, whereas, as previously reported (Li et al., 2002a) , minimal STAT5 activity was detected in the mammary glands of wild-type and Thrb þ / þ Pten þ /À littermates. Consistent with the stimulatory effect of STAT5 signaling on cell proliferation, we observed a strong increase in epithelial cell proliferation in the mammary glands of Thrb PV/ þ Pten þ /À mice together with a dramatic augmentation in the expression level of the STAT5 target gene, Csn2.
Determination of PRL concentrations in the serum and in the pituitary showed no significant increase that could account for STAT5 overactivation in Thrb PV/ þ Pten þ /À mammary glands. We postulated that endogenous TRb and TRbPV could regulate STAT5 activity. Cell-based studies with a PRL-responsive breast cancer cell line, T47D, showed that STAT5 activity was significantly repressed by T3 in TRb-expressing cells. However, the T3-induced repression of STAT5 activity did not occur in TRbPV-expressing cells, consistent with the fact that TRbPV has lost T3 binding capacity. STAT5 signaling was repressed by T3 in TRb-expressing cells through decreasing STAT5-mediated transcription activity and target gene expression, whereas sustained STAT5 activity was observed in TRbPV-expressing cells. Thus, these results suggest that TRbPV leads to persistent activation of the STAT5 signaling to stimulate cell proliferation, thereby contributing to mammary hyperplasia.
In summary, this report indicates that the ThrbPV mutation increases the occurrence of mammary epithelial hyperplasia and mammary tumors in nulliparous females through aberrant activation of the STAT5 pathway. The increased susceptibility of mammary gland abnormalities is not found in heterozygous ThrbPV mice, but in homozygous ThrbPV mice, suggesting that gene dosage is important. The observation that mice heterozygous for ThrbPV but deficient in Pten exhibit a high occurrence of mammary gland hyperplasia and tumors suggests the existence of a genetic interaction between ThrbPV signaling and Pten to contribute to mammary gland abnormalities. It was reported that Pten deficiency leads to phosphatidylinositol 3-kinase/Akt signaling overactivation in the mammary glands (Li et al., 2002a; Alimonti et al., 2010) . Consistent with these findings, we observed an increased activation of the phosphatidylinositol 3-kinase/Akt pathway in the mammary glands of Thrb
and Thrb PV/ þ Pten þ /À mice as assessed by western blot analysis of phosphorylated and total Akt (Supplementary Figure A) . Therefore, it may be hypothesized that the overactivation of the phosphatidylinositol 3-kinase/ Akt signaling pathway due to Pten deficiency together with the overactivation of STAT5 pathway resulting from the ThrbPV mutation are required for mammary gland hyperplasia and tumors. Collectively, our work shows for the first time that a TRb mutation predisposes to the development of mammary preneoplastic lesions. Moreover, it would be of interest to assess the impact of different THRB mutations or of THRB loss on the mammary gland in the Pten þ /À mouse model. Besides, because the relation between thyroid status and the pathogenesis of breast cancer is still being debated, further studies are required to analyze the effect of hypo-and hyper-thyroidism on the occurrence of mammary preneoplasia in these mice.
The novel findings from this study have important clinical implications. Germ-line inactivating mutations of PTEN are commonly associated with breast tumors in Cowden's syndrome patients. Moreover, several studies revealed the occurrence of somatic PTEN inactivation in sporadic human breast tumors (Lynch et al., 1997; Rhei et al., 1997; Banneau et al., 2010) . Similarly, THRB mutations have been reported in breast tumors (Silva et al., 2002) . Given the dual involvement of Thrb mutation and Pten deficiency in mouse mammary tumorigenesis shown in this study, it would be of importance to search for genetic alterations in both genes in human breast tumors. Thus, the identification of a TRb mutation as a potential oncogene has provided new insights into tumorigenesis of the breast, and thereby provides new therapeutic strategies.
Materials and methods

Mice and T47D cell line
The care and handling of the animals used in this study were approved by the National Cancer Institute Animal Care and Use Committee. Mice harboring the Thrb PV gene (Thrb
and Thrb PV/PV mice) were prepared and genotyped as described earlier (Kaneshige et al., 2000) . Pten þ /À mice were kindly provided by Dr Ramon Parsons (Columbia University, New York, NY, USA; (Podsypanina et al., 1999) 
mice were obtained by crossing Pten þ /À mice with Thrb PV/ þ mice, and then Thrb PV/ þ Pten þ /À males were crossed with Pten þ /À females to obtain the different genotypes for our study:
Littermates with a similar genetic background were used in all experiments. The human breast cancer cell line T47D was generously provided by Erika Ginsburg (NCI, Bethesda, MD, USA).
Whole-mount mammary gland staining and histology For whole-mount staining, the fourth mammary glands were spread on microscope slides, and fixed in a mix of glacial acetic acid (1 volume) and ethanol 100% (3 volumes) overnight or longer. They were then hydrated in ethanol 70% and tap-distilled water, and stained with carmine alum stain (1% carmine, 2.5% aluminum potassium sulfate, Sigma, St Louis, MO, USA) overnight or longer, at room temperature. After staining, the slides were dehydrated through increasing ethanol concentrations, cleared in xylene (Sigma) and mounted with Permount (Fisher Scientific, Hudson, NH, USA). Mammary glands, lungs and lymph nodes were dissected and embedded in paraffin. Sections of 5-mm thickness were prepared and stained with hematoxylin and eosin (HistoServ, Germantown, MD, USA). For each animal, single random sections through the mammary gland and the lung were examined by our pathologist (Mark C Willingham). For mammary gland, morphological evidence of a single section of fibroadenoma and adenocarcinoma was routinely counted. Evidence of any of these changes in any section was counted as positive for that change.
RNA extraction and real-time reverse transcriptase-PCR Total RNA from mammary glands was isolated using TRIzol (Invitrogen, Carlsbad, CA, USA) as indicated by the manufacturer's protocol. Real-time reverse transcriptase-PCR was carried out using a QuantiTect SYBR green reverse transcriptase-PCR kit (Qiagen, Valencia, CA, USA) following the manufacturer's instructions. Primers were as followed: bcasein, Csn2 forward: 5 0 -CCTTGCCAGTCTTGCTAATC-3 0 ; Csn2 reverse: 5 0 -GAATGTGGAGTGGCAG-3 0 . Gapdh (glyceraldehyde-3-phosphate dehydrogenase), forward: 5 0 -ACATCA TCCCTGCATCCACT-3 0 ; Gapdh, reverse, 5 0 -GTCCTCAGTGT AGCCCAA-3 0 .
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed paraffin mammary sections, as previously described (Guigon et al., 2009 
Western blot analysis
Mammary gland tissues were homogenized on ice in lysis buffer containing 50 mM Tris, 100 mM HCl, 0.1% Triton X-100, 0.2 mM okadaic acid, 100 mM NaF and 2 mM Na 3 VO 4 , and a proteinase inhibitor tablet (Complete Mini EDTA-free; Roche, Mannheim, Germany), followed by incubation on ice for 10 min with occasional vortexing. The lysate was centrifuged for 5 min at 20 000g at 4 1C, and the supernatant was collected. The protein concentration for each lysate was determined by the Bradford assay (Pierce Chemical, Rockford, IL, USA) using bovine serum albumin (Pierce Chemical) as the standard. The protein sample (40 mg) was loaded and separated by SDS-polyacrylamide gel electrophoresis. After electrophoresis, the protein was electrotransferred to a polyvinylidene difluoride membrane (Immobilon-P; Millipore, Bedford, MA, USA). Antibodies used: phospho-STAT5A/B (Tyr694/699) (dilution 1:1000; Millipore, #05-495), total STAT5A/B (dilution 1:1000), phosphorylated Akt (Ser473, #9363), total Akt (#9272) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (dilution 1:1000; #2118) from Cell Signaling Technologies, cyclin D1 (dilution 1:200; Santa Cruz Biotechnologies, Santa Cruz, CA, USA, sc-450) and anti-Flag antibody (dilution 0.5 ug/ml; Sigma, #F7425). Band intensities were quantified by using NIH IMAGE software (ImageJ 1.34s; Wayne Rashband, NIH) (http://rsb.info.nih.gov/ij).
Expression of Flag-TRb and Flag-TRbPV in the breast cancer T47D cell line Adenoviral constructs encoding Flag-tagged TRb and TRbPV or the empty vector were generated by Dom Esposito's cloning Optimization Group, and adenovirus production was performed by Viral Technology Laboratory in NCI-Fredrick/ NIH. 8 Â 10 5 T47D cells per 60-mm dishes (for protein expression studies) or 2.5 Â 10 6 T47D cells per 10-cm dishes (for immunoprecipitation studies) were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum, insulin (1 mg/ml) and 1 mM of glutamine for 24 h. Adenovirus infection was performed in OptiMEM (Invitrogen) at a multiplicity of infection of 10. After 2 h, the medium was changed with RPMI1640 containing 10% T3-depleted (Td) serum. After 18 h of culture, cells were treated with or without human prolactin (200 ng/ml, Sigma #L4021) and T3 (100 nM) for 5 or 24 h. Cells were then lysed and protein extracted as previously described (Guigon et al., 2008) .
Luciferase assays T47D cells were plated at a density of 1 Â 10 5 cells per well in 12-well plates. After 24 h, cells were cultured in serum-free OptiMEM1 and transfected with pcDNA3.1-TRb, pcDNA3.1-TRbPV or the pcDNA3.1 plasmid, and the reporter plasmid pGL4-CISH (generously provided by Dr Clevenger, (Fang et al., 2008) ) using Lipofectamine2000 (Invitrogen), according to the manufacturer's protocol. After a 7-h incubation, transfection medium was replaced by fresh Dulbecco's modified Eagle's medium containing 10% T32-depleted calf serum. Eighteen hours later, cells were cultured with or without T3 (100 nM) and PRL (200 ng/ml) for an additional 5 h. Cells were lysed in reporter lysis buffer (3 Â cell lysis buffer; BD Bioscience Pharmingen, Franklin Lakes, NJ, USA). Lysates were assayed for luciferase activity and normalized to total protein concentration.
Statistical analysis
Data are expressed as mean ± s.e.m. Statistical analysis was performed with the use of analysis of variance, and Po0.05 was considered significant unless otherwise specified. GraphPad Prism 5.0a (San Diego, CA, USA) was used to perform Kaplan-Meier cumulative survival analysis, and unpaired Student's t-test, with Welch's correction when variances were unequal.
